article thumbnail

Building the Disease Biology Generative AI Platform for Pharma R&D

BenchSci

Earlier this month, I traveled across North America and the UK to meet our 340 team members. Every year in January, we kick off the year with our “Roadshow”, where I meet our team in person and share our accomplishments and learning from the previous year and where we are going next.

article thumbnail

Mapping the GenAI Landscape in Pharma R&D

BenchSci

This surge has demonstrated to budget holders and decision-makers alike the significant impact AI can have when effectively applied, offering immense potential to accelerate drug discovery and development across various stages, from unraveling the complexity of disease biology to refining drug design and expediting clinical trials.

article thumbnail

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D

The Pharma Data

Boehringer Ingelheim is significantly increasing its investment in a broad range of digital technologies, encompassing key areas such as Artificial Intelligence (AI), machine learning, and data science to better understand diseases, their drivers and biomarkers, and digital therapeutics.